BTK and B-cell chronic lymphocytic leukemia: Slow recovery of BTK activity due to new synthesis of enzyme in human subjects was also seen after acalabrutinib treatment in patients with chronic lymphocytic leukemia, where a short half-life of plasma concentrations of 1h was observed (65), yet only a 25.6% of free BTK was recovered by 48h post last dose (66).